Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
JSVCT088
Phase 1 mab completed
Quick answer
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for COVID-19 is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- COVID-19
- Phase
- Phase 1
- Modality
- mab
- Status
- completed